Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 5/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12583719 | 0.92 | CA9 (0.57) | CA9ACACBESR1ESR2LTA4H | |
| SCHEMBL5802907 | 0.83 | MEN1 (0.50) | KDM4EGAAMAPTDRD2 | |
| SCHEMBL3054852 | 0.79 | CA9 (0.62) | CA9ESR1ESR2LTA4HABCB1 | |
| SCHEMBL12151204 | 0.78 | CHKA (0.54) | CA9ACACBESR1ESR2ABCB1 | |
| SCHEMBL23395349 | 0.77 | ESR2 (0.55) | CA9ESR1ESR2LTA4HDRD2 | |
| SCHEMBL5451645 | 0.77 | KDM4E (0.43) | KDM4EGAAMAPT | |
| SCHEMBL3041525 | 0.76 | CA9 (0.73) | CA9ABCB1ABCC1ABCG2KDM4E | |
| SCHEMBL23395285 | 0.75 | ESR2 (0.52) | CA9ESR1ESR2DRD2DRD1 | |
| SCHEMBL10675304 | 0.75 | ABCB1 (0.62) | CA9LTA4HABCB1ABCC1ABCG2 | |
| SCHEMBL3061384 | 0.74 | CA9 (0.70) | CA9LTA4HABCB1ABCC1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738710-B2 | Method of treating a patient for pain by administering an anti-ion channel antibody | UCB BIOPHARMA SPRL (BE) | 2017-08-22 | — | — | US | disclosed |
| US-20160222107-A1 | METHODS OF TREATING PAIN USING FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB BIOPHARMA SPRL (BE) | 2016-08-04 | — | — | US | disclosed |
| US-9266953-B2 | Methods of treating pain using function modifying NAv1.7 antibodies | UCB BIOPHARMA SPRL (BE) | 2016-02-23 | — | — | US | disclosed |
| US-20150232553-A1 | FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB PHARMA S.A. (BE) | 2015-08-20 | — | — | US | disclosed |
| US-20150203571-A1 | ANTIBODIES TO ION CHANNELS | UCB BIOPHARMA SPRL (BE) | 2015-07-23 | — | — | US | disclosed |
| US-8926977-B2 | Antibodies to the E1 extracellular loop of ion channels | UCB PHARMA S.A. (BE) | 2015-01-06 | — | — | US | disclosed |
| US-20140342406-A1 | DNA ENCODING FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB PHARMA S.A. (BE) | 2014-11-20 | — | — | US | disclosed |
| US-8734798-B2 | Function modifying NAv 1.7 antibodies | UCB PHARMA S.A. (BE) | 2014-05-27 | — | — | US | disclosed |
| US-20120259096-A1 | ANTIBODIES TO ION CHANNELS | UCB PHARMA S.A. (BE) | 2012-10-11 | — | — | US | disclosed |
| US-20110135662-A1 | FUNCTION MODIFYING NAv 1.7 ANTIBODIES | UCB BIOPHARMA SPRL (BE) | 2011-06-09 | — | — | US | disclosed |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259096-A1 | ANTIBODIES TO ION CHANNELS | SCN1A, KCNAB1, KCNMA1 | CA9 4076/4885ACACB 4591/4885ESR1 2581/4885 |
| US-20110135662-A1 | FUNCTION MODIFYING NAv 1.7 ANTIBODIES | SCN7A, SCN1A, SCN5A | CA9 4385/4885ACACB 4302/4885ESR1 4509/4885 |
| US-20150203571-A1 | ANTIBODIES TO ION CHANNELS | SCN1A, KCNAB1, KCNMA1 | CA9 4076/4885ACACB 4591/4885ESR1 2581/4885 |
| US-20160222107-A1 | METHODS OF TREATING PAIN USING FUNCTION MODIFYING NAv1.7 ANTIBODIES | SCN7A, SCN3A, SCN1A | CA9 2940/4885ACACB 4224/4885ESR1 4613/4885 |
| US-20150232553-A1 | FUNCTION MODIFYING NAv1.7 ANTIBODIES | SCN7A, SCN1A, SCN5A | CA9 4176/4885ACACB 4533/4885ESR1 4615/4885 |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | CA9 2226/4885ACACB 3033/4885ESR1 4391/4885 |
| US-20140342406-A1 | DNA ENCODING FUNCTION MODIFYING NAv1.7 ANTIBODIES | SCN7A, SCN1A, SCN8A | CA9 4042/4885ACACB 4604/4885ESR1 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.